Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

NCT02004691 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Sphingomyelin Lipidosis

Interventions

DRUG: placebo (saline)
DRUG: Olipudase alfa

Sponsor

Genzyme, a Sanofi Company